The NIH Department is offering the RNAMoDO grant to promote mechanistic research into RNA modifications driving oncogenesis, specifically their central role in translational reprogramming of cancer cells. This grant is for investigating how dysregulation of mRNA, tRNA, and rRNA modifications reprograms translation to fuel tumor initiation, progression, and therapy adaptation. While RNA modifications significantly impact gene expression, the molecular mechanisms underlying their effect on the translatome, especially interactions between different modifications, remain unclear. This initiative seeks collaborative, multi-PI projects that explore how modifications in mRNA, tRNA, and rRNA drive oncogenesis through translational reprogramming. Successful proposals must also examine the impact of interactions between modifications on the same or different RNA molecules during translation to advance understanding in this critical emerging field.
Opportunity ID: 355707
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-24-029 |
| Funding Opportunity Title: | RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 29, 2024 |
| Last Updated Date: | Jul 29, 2024 |
| Original Closing Date for Applications: | Nov 04, 2024 |
| Current Closing Date for Applications: | Nov 04, 2024 |
| Archive Date: | Dec 10, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | City or township governments County governments Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities For profit organizations other than small businesses Small businesses Native American tribal governments (Federally recognized) State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The overarching objective of this concept is to promote mechanistic research in the emerging area of RNA modifications that drive oncogenesis, with a focus on the central role of RNA modifications in translational reprogramming of cancer cells. RNA modifications have been recognized to exert a substantial impact on gene expression and function and their de-regulation has been linked to the cancer phenotype. In particular, recent insights point to a crucial role for mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation, progression, and adaptation to therapy. However, the molecular mechanisms underlying this reshaping of the translatome caused by dynamic changes in RNA modifications, and especially the interplay between different RNA modifications within and across RNA molecules during translation, are not understood and represent the focus of this initiative. Historically, the research community has largely pursued investigations of RNA modifications by studying single RNA species and modification types. However, elucidating how dysregulation of mRNA, tRNA, and rRNA modifications reprograms translation to drive oncogenesis is not likely feasible for any single research lab, but will require the combination of expertise in mRNA, tRNA and rRNA biology, translational regulation, and cancer research. To stimulate progress in this emerging field, the RNAMoDO program will support collaborative research projects, preferably using an MPI structure, on how modifications in mRNA, tRNA, and rRNA molecules can drive the oncogenic process through translational reprogramming. To be responsive to the NOFO, each project will also explore the impact of interactions between modifications residing on the same or different RNA molecules during translation. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-029.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 355707 Full Announcement-RFA-CA-24-029 -> RFA-CA-24-029-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00287512 | Oct 04, 2024 | Nov 04, 2024 | View |
Package 1
Mandatory forms
355707 RR_SF424_5_0-5.0.pdf
355707 PHS398_CoverPageSupplement_5_0-5.0.pdf
355707 RR_OtherProjectInfo_1_4-1.4.pdf
355707 PerformanceSite_4_0-4.0.pdf
355707 RR_KeyPersonExpanded_4_0-4.0.pdf
355707 PHS398_ResearchPlan_5_0-5.0.pdf
355707 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
355707 RR_Budget_3_0-3.0.pdf
355707 RR_SubawardBudget30_3_0-3.0.pdf
355707 PHS398_ModularBudget_1_2-1.2.pdf
355707 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
